Malvern Zetasizer Nano Provides Protein Insight for Both Students and Researchers at University of Massachusetts
News Jul 11, 2007
Malvern Instruments has announced that the user-friendliness of its Zetasizer Nano is proving to be a factor in its successful use in the Department of Chemistry at the University of Massachusetts (Amherst, MA, USA) for a wide range of protein applications.
The Zetasizer Nano is a protein characterization tool, one of a large range of analytical techniques used in the department.
Professor of Bioanalytical and Biophysical Chemistry, Paul Dubin, whose primary research interest is protein-polyelectrolyte complexes, said: “Malvern’s Zetasizer Nano is user-friendly, so everyone, including undergraduate students can get useful data right away. Its rapid data acquisition means that the time-dependence of a process can be followed.”
“The combination of dynamic and electrophoretic light scattering makes measurement of protein isoelectric point simple and precise. The cells are convenient for filtration and reasonably good for small volumes, important for conserving sample”
Professor Dubin and co-workers have cited the Zetasizer Nano in papers on mixed micelle growth, protein aggregation and polycation-immobilized micelles for groundwater remediation.
"Non-Gene" Mutations May Hold Answers to Neurodevelopmental DisordersNews
Mutations in non-coding regions of the genome, which don't contain genes, but control the regulation of other genes, may hold answers to rare developmental disorders that affect the nervous system.READ MORE
Majority of European Wolves Have Dog DNANews
The wolf may not often act like man's best friend, but a new study has found that the majority of wild wolves in Europe contain chunks of dog DNA. The finding is causing scientists to rethink what constitutes a wolfdog hybrid and how we approach conservation of keystone wolf populations.READ MORE
Neuroblastoma Biomarker Research Advances TreatmentNews
Neuroblastoma, a childhood cancer, is treatable in less than half of aggressive cases, but new RNA biomarkers may help identify high-risk patients faster and lead to better prognosis.READ MORE